Investigational drug · Phase 3
Ceralasertib
Also called: AZD6738
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Melanoma, Advanced or Metastatic NSCLC, Non-Small Cell Lung Cancer.
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
47
Any phase or sponsor naming "Ceralasertib"
First trial start
2017
Dec 18, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ceralasertib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Melanoma
- Advanced or Metastatic NSCLC
- Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-Small Cell Lung Cancer
- Advanced Solid Tumours
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Ceralasertib" as an intervention, largest first.
- The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) TrialStatus unknown
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT03182634 · 1,150 participants (planned) · Start Dec 15, 2016 · Primary completion Nov 2022
Drug: Fulvestrant; Neratinib and 3 more · For: Advanced Breast Cancer
Sites: Sutton, United Kingdom; Bournemouth, United Kingdom; Bristol, United Kingdom · 19 sites in all
- Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT06769126 · 900 participants (planned) · Start Nov 6, 2025 · Primary completion Dec 31, 2028
Drug: Ceralasertib; Durvalumab and 4 more · For: Extensive Stage Lung Small Cell Carcinoma; Lung Small Cell Carcinoma, A Subtype; Lung Small Cell Carcinoma, I Subtype and 2 more
Sites: Loma Linda, California; Rancho Mirage, California; Sacramento, California · 148 sites in all
- Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung CancerPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT06732401 · 630 participants (planned) · Start Aug 7, 2025 · Primary completion Jun 30, 2028
Drug: Ceralasertib; Durvalumab · For: Lung Non-Small Cell Carcinoma; Stage II Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8 and 1 more
Sites: Jonesboro, Arkansas; Beverly Hills, California; Los Angeles, California · 192 sites in all
- A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT05450692 · 594 participants · Start Sep 15, 2022 · Primary completion Oct 6, 2025
Drug: Ceralasertib; Durvalumab and 1 more · For: Advanced or Metastatic Non-Small Cell Lung Cancer
Sites: Mobile, Alabama; Chandler, Arizona; Los Alamitos, California · 191 sites in all
- Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03334617 · 528 participants · Start Dec 18, 2017 · Primary completion Sep 13, 2024
Drug: Durvalumab; Danvatirsen and 6 more · For: Non-Small Cell Lung Cancer
Sites: Duarte, California; Fullerton, California; La Jolla, California · 45 sites in all
Gustave Roussy, Cancer Campus, Grand ParisAcademic, hospital or other
NCT02813135 · 472 participants (planned) · Start Aug 3, 2016 · Primary completion Feb 2031
Drug: Ribociclib; Topotecan and 22 more · For: Pediatric Cancer
Sites: Copenhagen, Denmark; Villejuif, France; Angers, France · 23 sites in all
University of BirminghamAcademic, hospital or other
NCT02664935 · 423 participants · Start May 13, 2015 · Primary completion Nov 29, 2023
Drug: AZD4547; Vistusertib and 9 more · For: Non-Small Cell Lung Cancer; Carcinoma, Squamous Cell; Adenocarcinoma
Sites: Aberdeen, United Kingdom; Belfast, United Kingdom; Birmingham, United Kingdom · 25 sites in all
- Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer AgentsActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT02264678 · 358 participants · Start Oct 31, 2014 · Primary completion Mar 4, 2025
Drug: Administration of ceralasertib; Administration of ceralasertib in combination with olaparib and 6 more · For: Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Sites: Duarte, California; Irvine, California; Los Angeles, California · 28 sites in all
- To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.Pivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03330847 · 273 participants · Start Mar 7, 2018 · Primary completion Nov 13, 2020
Drug: Olaparib Continuous (28-Day cycle) 300 mg BD.; Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle). and 1 more · For: Metastatic Triple Negative Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Gilbert, Arizona · 141 sites in all
- A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLCPivotal-lookingRecruiting
University of LeedsAcademic, hospital or other
NCT04550104 · 200 participants (planned) · Start Mar 17, 2021 · Primary completion Mar 2026
Drug: Olaparib Oral Tablet [Lynparza]; AZD1390 and 3 more · For: Non Small Cell Lung Cancer
Sites: Belfast, United Kingdom; Birmingham, United Kingdom; Cambridge, United Kingdom · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Design, synthesis and anti-breast cancer activity evaluation of 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine-based PARP1/ATR dual inhibitors.
He ML, Wang ZH, Yao X, et al. · J Enzyme Inhib Med Chem 2026
- Ceralasertib plus Durvalumab in Ras Mutant and Ras Wild-Type Advanced Non-Small Cell Lung Cancer: Two Cohorts of the Phase II Platform National Lung Matrix Trial.
Middleton G, Buchanan R, Savage J, et al. · Clin Cancer Res 2026
- Quantitative systems pharmacology modeling identifies synthetic lethality opportunities with DNA damage response inhibitors in ATM-deficient chronic lymphocytic leukemia - a computational simulation study.
Bharath Kumar G, Mishra A, Archana AS, et al. · J Pharmacokinet Pharmacodyn 2026
- Ataxia Telangiectasia and Rad3-Related Kinase as a Drug Target and Its Inhibitors: Synthetic Aspects, Current Research and Potential Perspectives.
Bhagwat P, Kirubakaran S · Arch Pharm (Weinheim) 2026
- Mechanistic insights into phosphorylation-driven activation and therapeutic inhibition of human ATR-ATRIP.
Wang L, Wang M, Zhao L, et al. · Nat Struct Mol Biol 2026
- ATR inhibitors synergise with mitomycin C to enhance cytotoxicity in patient-derived non-muscle invasive bladder cancer organoids.
Zuidema A, Nijland L, van Megesen K, et al. · Br J Cancer 2026
Also in development for Melanoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- Intismeran autogeneV940, mRNA-4157Phase 310 trials
Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- IBI363Phase 37 trials
Innovent Biologics (Suzhou) Co. Ltd. · Melanoma, Colorectal Cancer, Resectable Stage II-III Non-small Cell Lung Cancer
- OH2Phase 36 trials
Binhui Biopharmaceutical Co., Ltd. · Melanoma, Solid Tumor, Gastrointestinal Cancer
- PucotenlimabHX008Phase 36 trials
Lepu Biopharma Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Melanoma, Hepatocellular Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.